Actively Recruiting
Predictors of Node Positivity in Endometrial Cancer
Led by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · Updated on 2024-09-19
200
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate the role of histological and moleculr profile of endometrial cancer patietns in predicting the risk of nodal metastases in endometrila cancer patients.
CONDITIONS
Official Title
Predictors of Node Positivity in Endometrial Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written informed consent
- Histologically confirmed endometrial cancer
- Data on molecular genomic profiling (POLE mutated, p53 abnormalities, MMRd/MSI-H, and NSMP)
- Data on histological characteristics of the tumor
- Execution of sentinel node mapping
- Data on sentinel node status (negative vs. positive)
You will not qualify if you...
- Stage IVB endometrial cancer
- Consent withdrawal
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, Italy, 20148
Actively Recruiting
Research Team
G
Grazia M Casadei, ph.d.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here